Navigation Links
NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
Date:2/27/2008

forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding the timing of potential commercial launch of NGX- 4010; the timing of filings for regulatory approval and the indications potentially being sought in such filings; the indications for which NGX-4010 may be approved for use; the potential markets for NGX-4010; the potential efficacy and benefits of NGX-4010; the potential use of data from the recently completed clinical trial in HIV-DSP to support efficacy; and NeurogesX' plans to commercialize NGX-4010, including with respect to sales force plans and plans to enter into commercial partnerships. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, data from the recently completed clinical trial in HIV-DSP may have an effect on the potential regulatory approval of NGX-4010, and approved indications of such approval, if any; positive results in certain clinical trials may not be sufficient to obtain FDA or European regulatory approval; subsequent analysis of data from NeurogesX' past clinical trials may cause the results to be viewed less favorably as compared to the initial analysis of such results; past results of clinical trials may not be indicative of future clinical trials results; NGX-4010 may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use NGX- 4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies and changing standards of care; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; NeurogesX' ability to obtain additional financing; NeurogesX' ability to obtain and maintain futur
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
9. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... CHAPEL HILL, N.C. , July 2, 2015 ... their own employees to capture critical product and ... there are many benefits to employee-based studies, it ... to leverage their own internal employees to capture ... recent study by benchmarking firm, Best Practices, LLC, ...
(Date:7/2/2015)... ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2015 results on Thursday, July 30, 2015, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:7/2/2015)... 2015  Fort Lauderdale-based investment banking firm, Farlie ... its Consumer Group completed the sale of Insight ... (ISE: KRZ) ("Kerry"), one of the leading global ... well as functional ingredients and actives for the ... served as the exclusive financial advisor to the ...
Breaking Medicine Technology:Leveraging Employee Insights to Produce Cutting-Edge Market Research 2ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2
(Date:7/3/2015)... ... July 03, 2015 , ... B. ... has been retained to lead a national chief nursing officer recruitment ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:7/3/2015)... St. Louis, MO (PRWEB) , ... July 03, 2015 , ... ... new responsive website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just ... for talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer ...
(Date:7/3/2015)... ... ... Selfie on a Stick ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... smartphone has an incredibly powerful camera built into it. And when someone is traveling ...
(Date:7/3/2015)... ... July 03, 2015 , ... The Celebrity Dresses is currently running a ... those of celebrities will have the opportunity to get 10% discount on orders that ... people do not have to use coupon codes or remember redemption codes. , ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest ... the Lone Star State. The premium frozen yogurt chain was listed as #22 on ... opened July 1 at Duke’s Travel Plaza, is located at:, 30176 Hwy 64, Suite ...
Breaking Medicine News(10 mins):Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2
... HealthCare announced today that it awarded 20 individuals from ... Bayer Hemophilia Awards Program (BHAP). As the largest program ... and educational initiatives around the world. Recipients were selected ... treatment and care and were honored last evening during ...
... , TULSA, Okla., July 14 ... to present a unified front representing Independent Diagnostic Testing Facilities ... medical imaging industry personnel and diagnostic clinics. The association will ... procedures that often promote early detection of cancer. , ...
... , , , , ... ) announced that it beat its original goal for first time fundraising event ... a target of $250,000. To date, it has raised more than $280,000. ... , According to Anthony Mann, founder of the bike ...
... , , ... today that its SNICKERS(R) Brand is teaming up with Feeding America to ... struggling with hunger(1). As part of ,Bar Hunger, SNICKERS ... to Feeding America in 2009. The brand will also educate and ...
... ... under the knife? Advances in fractional laser technology have resulted in the Fractional Eyelift, a ... Bruce Katz of the Juva Skin & Laser Center pioneered the procedure. , ... (PRWEB) July 14, 2009 -- For many, ...
... , VIENNA, Austria, July 14 Changes in the brain ... of risk proteins in body fluids, may lead to earlier and more ... Alzheimer,s Association 2009 International Conference on Alzheimer,s Disease (ICAD 2009) in Vienna. ... http://www.newscom.com/cgi-bin/prnh/20090529/ICADLOGO ) , ...
Cached Medicine News:Health News:Bayer HealthCare Awards $2.5 Million to Advance Hemophilia Research and Improve Patient Care 2Health News:Bayer HealthCare Awards $2.5 Million to Advance Hemophilia Research and Improve Patient Care 3Health News:Bayer HealthCare Awards $2.5 Million to Advance Hemophilia Research and Improve Patient Care 4Health News:Bayer HealthCare Awards $2.5 Million to Advance Hemophilia Research and Improve Patient Care 5Health News:New Medical Imaging Organization Launched to Represent Industry Personnel and Diagnostic Clinics 2Health News:JBFCS Surpasses Fundraising Goal For Hudson Valley Bike Ride Despite Difficult Financial Times 2Health News:SNICKERS(R) Brand and David Arquette Make a Big Move to Help Feeding America Bar Hunger 2Health News:SNICKERS(R) Brand and David Arquette Make a Big Move to Help Feeding America Bar Hunger 3Health News:SNICKERS(R) Brand and David Arquette Make a Big Move to Help Feeding America Bar Hunger 4Health News:Fractional Eyelift Procedure Reduces Eyelid Drooping and Wrinkles with Minimal Recovery Time 2Health News:Fractional Eyelift Procedure Reduces Eyelid Drooping and Wrinkles with Minimal Recovery Time 3Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 2Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 3Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 4Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 5Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 6Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 7Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 8
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... 1-step, hand-held, point-of-care device for the qualitative detection ... The TOX/See device can detect up to ... 3 to 8 minutes and requires only a ... individually packaged to maximize convenience and ease of ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: